# Safety of RSV Preventive Monoclonal Antibody

> **NCT07158814** · PHASE4 · RECRUITING · sponsor: **Duke University** · enrollment: 524 (estimated)

## Conditions studied

- Fever
- Adverse Event Following Immunisation

## Interventions

- **DRUG:** Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody

## Key facts

- **NCT ID:** NCT07158814
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2027-02
- **Final completion:** 2027-04
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158814, "Safety of RSV Preventive Monoclonal Antibody". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07158814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*